Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

The Phase III GRADIENT trial for relacorilant has missed its primary endpoint of improving SBP for Cushing's syndrome ...

Corcept Therapeutics Incorporated CORT has been having a fabulous 2024, with its share price increasing 60.5% year to date as of Nov. 5, 2024. This company engages in the discovery and development of ...

Robeco Institutional Asset Management B.V. decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 66.6% in the 3rd quarter, according to its most ...

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

Corcept Therapeutics (NASDAQ:CORT) is gearing up to announce its quarterly earnings on Wednesday, 2024-10-30. Here's a quick overview of what investors should know before the release. Analysts are ...

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has received an average recommendation of “Buy” from the five brokerages that are covering the company, MarketBeat reports.

Corcept Therapeutics (CORT) shares soared 5.5% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session.

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast Truist Securities raises the price target for Corcept Therapeutics to $76 ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...